Regenerative Medical Technology (RMTG) EBITDA (2018 - 2026)
Regenerative Medical Technology (RMTG) posted EBITDA of $632402.0 for Q2 2026, up 108.65% on a QoQ basis from $303092.0 in Q1 2026, and up 387.93% year-over-year from $129610.1 in Q2 2025.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) EBITDA (2018 - 2026) Analysis & Trends
Regenerative Medical Technology has reported EBITDA for 9 years, with the latest figure at $632402.0 in Q2 2026.
- On a quarterly basis, EBITDA rose 387.93% year-over-year to $632402.0 in Q2 2026; TTM through Jun 2026 was $309110.0, a 12.99% decrease from a year earlier, with the FY2025 full-year figure at -$683635.0, down 434.79% from the prior year.
- EBITDA was $632402.0 for Q2 2026 at Regenerative Medical Technology, up from $303092.0 in the prior quarter.
- The five-year high for EBITDA was $632402.0 in Q2 2026, with the low at -$2.5 million in Q4 2022.
- Average EBITDA over 5 years is -$192746.8, with a median of -$92270.5 recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: EBITDA surged 624.94% in 2024, then tumbled 568.62% in 2025.
- Over 5 years, EBITDA stood at -$2.5 million in 2022, then surged by 97.5% to -$62564.0 in 2023, then soared by 624.94% to $328422.0 in 2024, then sank by 170.74% to -$232316.0 in 2025, then soared by 372.22% to $632402.0 in 2026.
- The last three EBITDA figures came in at $632402.0 (Q2 2026), $303092.0 (Q1 2026), and -$232316.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.31 Bn | 9.47 Bn | 112.79 Mn | 58.42 Mn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -117.27 Mn |
| 3 | Iovance Biotherapeutics | 3.67 Bn | 3.37 Bn | 55.72 Mn | -51.91 Mn |
| 4 | Legend Biotech | 3.57 Bn | 2.60 Bn | 251.50 Mn | 57.70 Mn |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -52.20 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -126.55 Mn |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn | 22.64 Mn |
| 8 | Sarepta Therapeutics | 2.17 Bn | 1.37 Bn | 251.87 Mn | 13.29 Mn |
| 9 | Vericel | 1.96 Bn | 1.80 Bn | 56.40 Mn | 434,000.00 |
| 10 | Regenerative Medical Technology | 1.18 Mn | -139,694.93 | 2.58 Mn | 632,402.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 632,402.00 |
| Mar 31, 2026 | 303,092.00 |
| Dec 31, 2025 | -232,316.00 |
| Sep 30, 2025 | -394,068.00 |
| Jun 30, 2025 | -219,640.00 |
| Mar 31, 2025 | 162,389.00 |
| Dec 31, 2024 | 328,422.00 |
| Sep 30, 2024 | 84,091.00 |
| Jun 30, 2024 | -155,395.00 |
| Mar 31, 2024 | -52,918.00 |
| Dec 31, 2023 | -62,564.00 |
| Sep 30, 2023 | 23,604.00 |
| Jun 30, 2023 | -372,966.00 |
| Mar 31, 2023 | -41,968.00 |
| Dec 31, 2022 | -2.50 Mn |
| Sep 30, 2022 | -121,977.00 |
| Jun 30, 2022 | -330,497.00 |
| Mar 31, 2022 | -515,613.00 |
| Dec 31, 2021 | -469,854.00 |
| Sep 30, 2021 | -9.00 Mn |